复发性非霍奇金淋巴瘤的临床试验
总计6808个结果
-
Masonic Cancer Center, University of Minnesota完全的
-
Teva Branded Pharmaceutical Products R&D, Inc.完全的侵袭性 B 细胞非霍奇金淋巴瘤具有 R-CHOP-21 诱导的中性粒细胞减少症的高风险德国, 意大利, 西班牙
-
The First Affiliated Hospital with Nanjing Medical...Nanjing Legend Biotech Co.招聘中
-
AbbVieGenentech, Inc.完全的
-
PrECOG, LLC.Genentech, Inc.完全的滤泡性淋巴瘤 | 非霍奇金滤泡性淋巴瘤 | 非霍奇金淋巴瘤,成人高级别美国
-
Genentech, Inc.完全的
-
National Cancer Institute (NCI)邀请报名
-
Austin HealthMerck KGaA, Darmstadt, Germany主动,不招人
-
Janssen Research & Development, LLCCity of Hope Medical Center招聘中
-
Chinese PLA General Hospital招聘中
-
Hoffmann-La Roche完全的
-
Rhizen Pharmaceuticals SA完全的
-
Abramson Cancer Center of the University of Pennsylvania终止
-
University Hospital Tuebingen完全的
-
University Hospital Tuebingen完全的
-
Gruppo Italiano Multiregionale per lo studio dei...University of Turin, Italy; Fondazione Italiana Linfomi ONLUS; Centro di Riferimento per l'Epidemiologia...完全的
-
Jennifer Amengual完全的
-
Bristol-Myers Squibb招聘中
-
National Cancer Institute (NCI)主动,不招人Ann Arbor III 期非霍奇金淋巴瘤 | Ann Arbor IV 期非霍奇金淋巴瘤 | 实体肿瘤美国
-
Roswell Park Cancer InstituteNovartis终止
-
Spectrum Pharmaceuticals, IncThe Leukemia and Lymphoma Society终止
-
Gustave Roussy, Cancer Campus, Grand ParisSociété Française des Cancers et Leucémies de l'Enfant et de l'Adolescent (SFCE)完全的
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)完全的
-
Kjeld SchmiegelowOdense University Hospital; Aarhus University Hospital Skejby; Aalborg University Hospital撤销
-
Seagen Inc.Genentech, Inc.完全的